YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β‐catenin axis
Authors:
Open Access
- 27 April 2024
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 26 (5) , e3689
Abstract
Background: Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy characterized by a poor prognosis and closely linked to tumor stemness. However, the key molecules that regulate ICC stemness remain elusive. Although Y‐box binding protein 1 (YBX1) negatively affects prognosis in various cancers by enhancing stemness and chemoresistance, its effect on stemness and cisplatin sensitivity in ICC remains unclear.Methods: Three bulk and single‐cell RNA‐seq datasets were analyzed to investigate YBX1 expression in ICC and its association with stemness. Clinical samples and colony/sphere formation assays validated the role of YBX1 in stemness and sensitivity to cisplatin. AZD5363 and KYA1979K explored the interaction of YBX1 with the phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (PKB/AKT) and WNT/β‐catenin pathways.Results: YBX1 was significantly upregulated in ICC, correlated with worse overall survival and shorter postoperative recurrence time, and was higher in chemotherapy‐non‐responsive ICC tissues. The YBX1‐high group exhibited significantly elevated stemness scores, and genes linked to YBX1 upregulation were enriched in multiple stemness‐related pathways. Moreover, YBX1 expression is significantly correlated with several stemness‐related genes (SOX9, OCT4, CD133, CD44 and EPCAM). Additionally, YBX1 overexpression significantly enhanced the colony‐ and spheroid‐forming abilities of ICC cells, accelerated tumor growth in vivo and reduced their sensitivity to cisplatin. Conversely, the downregulation of YBX1 exerted the opposite effect. The transcriptomic analysis highlighted the link between YBX1 and the PI3K/AKT and WNT/β‐catenin pathways. Further, AZD5363 and KYA1979K were used to clarify that YBX1 promoted ICC stemness through the regulation of the AKT/β‐catenin axis.Conclusions: YBX1 is upregulated in ICC and promotes stemness and cisplatin insensitivity via the AKT/β‐catenin axis. Our study describes a novel potential therapeutic target for improving ICC prognosis.Keywords
This publication has 21 references indexed in Scilit:
- Current epidemiology of cholangiocarcinoma in Western countriesJournal of Hepatology, 2022
- Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?Cellular Signalling, 2022
- A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistanceCellular Signalling, 2021
- Y box binding protein 1 inhibition as a targeted therapy for ovarian cancerCell Chemical Biology, 2021
- Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinomaJournal of Hepatology, 2021
- Intrahepatic CholangiocarcinomaSurgical Oncology Clinics of North America, 2019
- ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic CholangiocarcinomaHepatology, 2018
- MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative PhosphorylationCell Metabolism, 2017
- Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarkerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2017
- Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y?Cell Death & Differentiation, 2013